Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18848235 | 0.93 | CHRNB2 (0.36) | ALDH1A1EPHX1ADRB2ADRB1ADRB3 | |
| SCHEMBL1883879 | 0.86 | ALDH1A1 (0.37) | ALDH1A1EPHX1ADRB2ADRB1ADRB3 | |
| SCHEMBL18792727 | 0.86 | ALDH1A1 (0.40) | ALDH1A1EPHX1ADRB2ADRB1ADRB3 | |
| SCHEMBL18631686 | 0.81 | ALDH1A1 (0.37) | ALDH1A1EPHX1ADRB2ADRB1ADRB3 | |
| SCHEMBL392016 | 0.81 | ALDH1A1 (0.38) | ALDH1A1EPHX1ADRB2ADRB1ADRB3 | |
| SCHEMBL10099631 | 0.80 | ALDH1A1 (0.50) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL3895683 | 0.80 | NAAA (0.35) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL1885005 | 0.79 | ALDH1A1 (0.37) | ALDH1A1EPHX1ADRB2ADRB1ADRB3 | |
| SCHEMBL390786 | 0.79 | ADRB2 (0.37) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL1890780 | 0.78 | NAAA (0.37) | ALDH1A1ADRB2ADRB1ADRB3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738620-B2 | Trientine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738620-B2 | Trientine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | SLC10A1, ABCB11, SLC10A2 | ALDH1A1 688/4885EPHX1 391/4885ADRB2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.